V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012027 | 330009320 | 1.7 | 92.2 | Not known (9) | 2015-10-05 | 2016-02-22 | Bortezomib + CYCLOPHOSPHAMIDE | N | null | 330015691 | CARBOPLATIN + VINCRISTINE |
| 330012028 | 330009322 | 1.7 | 83.8 | Curative (C) | 2014-09-22 | 2014-09-30 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | 330016127 | CYCLOPHOSPHAMIDE |
| 330012029 | 330012038 | 1.8 | 74 | Palliative (P) | 2014-11-28 | 2014-12-08 | CHOP R - 21 days | 2 | N | 330016564 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330012030 | 330006113 | 0 | null | Curative (C) | 2018-05-22 | 2018-05-22 | THALIDOMIDE + dexamethasone | N | N | 330020339 | VINCRISTINE |
| 330012031 | 330006116 | 0 | null | Neo-adjuvant (N) | 2013-06-10 | 2013-06-13 | Doxorubicin + Methotrexate | 02 | N | 330020434 | IFOSFAMIDE |
| 330012032 | 330006117 | 0 | null | Disease modification (D) | 2018-02-03 | 2018-02-25 | Carboplatin + Doxorubicin | N | N | 330020661 | CISPLATIN + GEMCITABINE |
| 330012033 | 330006119 | 0 | 77.9 | Palliative (P) | 2017-12-19 | 2017-12-19 | Abiraterone | 02 | N | 330020744 | BORTEZOMIB + RITUXIMAB |
| 330012034 | 330006120 | 1.78 | 64.5 | null | 2017-08-16 | 2018-02-01 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | N | N | 330020797 | CTD |
| 330012035 | 330009338 | null | 60 | Curative (C) | 2017-08-24 | 2017-11-28 | Doxorubicin + Methotrexate | Y | null | 330020858 | DHAP |
| 330012036 | 330006124 | 0 | 80.6 | Palliative (P) | 2017-12-06 | 2018-11-09 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | 330020918 | CAPECITABINE + CISPLATIN |
| 330012037 | 330009341 | null | 71.6 | Palliative (P) | 2018-02-20 | 2018-04-27 | Bevacizumab 5mg/kg | null | N | 330021072 | AML17 TRIAL |
| 330012038 | 330006128 | 1.6 | 67.9 | Palliative (P) | 2017-06-05 | 2017-06-25 | Cisplatin+Doxorubicin+Etoposide 28d | N | N | 330021091 | SUNITINIB |
| 330012039 | 330006131 | 1.74 | null | Disease modification (D) | 2018-02-15 | 2018-08-15 | ALL UKALL60+ TRIAL | 2 | N | 330021332 | BEP |
| 330012040 | 330011093 | 1.65 | 0 | Palliative (P) | 2018-07-25 | 2018-07-27 | AML18 PILOT TRIAL | N | N | 330021332 | CTD |
| 330012041 | 330006135 | null | 109 | Palliative (P) | 2017-02-19 | 2017-03-04 | Ifosfamide | N | Y | 330021705 | HYDROXYCARBAMIDE |
| 330012042 | 330006136 | 1.73 | 73.9 | Curative (C) | 2019-07-01 | 2019-07-01 | Carboplatin + Cetux + FU (>Cycle 2) | N | null | 330021777 | CAPECITABINE + CISPLATIN |
| 330012043 | 330006142 | 1.05 | 47.8 | Palliative (P) | 2017-05-16 | 2017-06-14 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | 330023337 | VIDE |
| 330012044 | 330013205 | 1.77 | 89.15 | Disease modification (D) | 2017-04-12 | 2017-04-22 | CNS LGG Irinotecan & Bevacizumab | N | null | 330023936 | BCG |
| 330012045 | 330006144 | 1.83 | 74 | Curative (C) | 2016-06-03 | 2016-06-14 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | N | 330024623 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330012046 | 330006148 | 1.74 | null | Curative (C) | 2017-01-07 | 2017-02-05 | UKALL14- Cons Cycle 2 | Y | N | 330025015 | CYCLOPHOSPHAMIDE |
| 330012047 | 330009350 | null | null | Palliative (P) | 2018-01-03 | 2018-02-16 | CAPECITABINE + VINORELBINE | N | N | 330003175 | IFOSFAMIDE |
| 330012048 | 330006152 | null | 64.1 | null | 2017-05-29 | 2017-06-08 | ALL UKALL2011 Consolidation A | N | N | 330007206 | CISPLATIN + VINORELBINE |
| 330012049 | 330006158 | null | 67 | null | 2019-01-28 | 2019-02-07 | UKALL14- Intens/CNS Proph | N | null | 330009579 | IPILIMUMAB |
| 330012050 | 330006163 | 1.77 | 54.6 | Curative (C) | null | 2018-07-08 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | null | null | 330020726 | FCR |
| 330012051 | 330002931 | 0 | 13.3 | Curative (C) | 2015-12-12 | 2016-07-09 | null | Y | Y | 330000004 | NOT MATCHED |
| 330012052 | 330002937 | null | 10.3 | Disease modification (D) | 2014-05-06 | 2014-05-06 | NB HRNBL-1 TVD | 02 | null | 330000050 | NOT MATCHED |
| 330012054 | 330002951 | 0 | 14.3 | Curative (C) | 2017-09-25 | 2018-06-06 | NB HRNBL-1 TVD | N | N | 330000081 | NOT MATCHED |
| 330012055 | 330007587 | null | 14 | Neo-adjuvant (N) | null | 2018-01-11 | CNS GCT II Non Germin - Std PEI | Y | N | 330000144 | NOT MATCHED |
| 330012056 | 330002972 | 0.98 | 24.7 | Curative (C) | 2017-03-09 | 2017-03-09 | NB HRNBL-1 COJEC Ind COURSE C | N | N | 330000172 | NOT MATCHED |
| 330012057 | 330002984 | 0 | 22.5 | Curative (C) | 2014-10-21 | 2015-01-07 | NB HRNBL-1 COJEC Ind COURSE A | 02 | null | 330000242 | NOT MATCHED |
| 330012058 | 330002989 | 0.78 | 14 | Palliative (P) | 2017-05-17 | 2017-05-17 | ETOPOSIDE + IFOSFAMIDE + METHOTREXATE | 02 | null | 330000247 | NOT MATCHED |
| 330012059 | 330002993 | 0.92 | 7.2 | Palliative (P) | 2016-07-25 | 2017-11-09 | NB HRNBL-1 Isotretinoin | N | N | 330000263 | NOT MATCHED |
| 330012060 | 330002995 | 1.1 | 12.2 | Neo-adjuvant (N) | 2016-05-08 | 2016-04-27 | NB HRNBL-1 COJEC Ind COURSE B | N | null | 330000276 | NOT MATCHED |
| 330012061 | 330003000 | 0 | 68.1 | Disease modification (D) | 2017-12-11 | 2018-01-12 | EW EuroEwing 2012 Arm B VC | 01 | N | 330000299 | NOT MATCHED |
| 330012062 | 330010144 | null | null | Neo-adjuvant (N) | 2014-12-01 | 2014-12-27 | NB HRNBL-1 COJEC Ind COURSE A | null | N | 330000305 | NOT MATCHED |
| 330012063 | 330003005 | null | 88.8 | Curative (C) | 2018-05-25 | 2018-05-29 | Cisplatin 100 + RT(H&N) 1 day | 2 | null | 330000310 | CISPLATIN + RT |
| 330012064 | 330003006 | null | 40 | Curative (C) | 2014-06-16 | 2017-10-13 | NB BEACON Temozolomide alone | Y | N | 330000334 | NOT MATCHED |
| 330012065 | 330003009 | 0.8 | 12.5 | Disease modification (D) | 2014-08-17 | 2016-08-13 | null | Y | null | 330000353 | NOT MATCHED |
| 330012066 | 330012741 | 0 | 11.2 | Disease modification (D) | 2017-10-26 | 2017-10-26 | CNS GCT II Germinoma - Ifos Etop | Y | null | 330000390 | NOT MATCHED |
| 330012067 | 330003017 | 0.93 | 34.9 | Curative (C) | null | 2016-11-07 | NB Rel CCLG guidelines Cyclo-Topotecan | Y | N | 330000391 | NOT MATCHED |
| 330012068 | 330003019 | null | 104.7 | null | 2017-08-25 | 2017-09-30 | Cisplatin + Radiotherapy | null | null | 330000392 | CISPLATIN + RT |
| 330012069 | 330007615 | 0 | 13.2 | Curative (C) | 2017-02-09 | 2017-09-07 | EW Rel rEECur Topotecan/Cyclophosphamide | N | N | 330000397 | NOT MATCHED |
| 330012070 | 330003028 | 0.92 | 19.2 | Adjuvant (A) | 2014-12-18 | 2015-04-09 | NB HRNBL-1 BUMEL MAT | 02 | N | 330000410 | NOT MATCHED |
| 330012071 | 330003033 | null | 37.8 | Palliative (P) | 2016-01-17 | 2016-03-18 | NB HRNBL-1 BUMEL MAT | N | N | 330000450 | NOT MATCHED |
| 330012072 | 330003045 | 0 | 59.05 | Curative (C) | 2013-07-23 | 2013-08-01 | NB HRNBL-1 COJEC Ind COURSE B | N | Y | 330000516 | NOT MATCHED |
| 330012073 | 330003053 | 0 | 7 | Curative (C) | 2013-05-09 | 2013-10-21 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | Y | 330000542 | NOT MATCHED |
| 330012074 | 330003058 | 1.8 | null | Not known (9) | 2017-02-13 | 2017-02-22 | Cisplatin + Radiotherapy | N | N | 330000589 | CISPLATIN + RT |
| 330012075 | 330003066 | 1.6 | 65.7 | Curative (C) | 2018-04-12 | 2018-07-02 | Cisplatin 100 + RT(H&N) 1 day | null | Y | 330000642 | CISPLATIN + RT |
| 330012076 | 330003072 | 0 | 98.4 | Not known (9) | null | 2016-11-14 | Cisplatin + Radiotherapy | 02 | Y | 330000651 | CISPLATIN + RT |
| 330012077 | 330003074 | null | 25.7 | Curative (C) | 2018-03-25 | 2018-04-05 | NB HRNBL-1 BUMEL MAT | Y | N | 330000652 | NOT MATCHED |